QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 2.070-2.570 for the period, compared to the consensus EPS estimate of 2.380. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of QuidelOrtho from $38.00 to $25.00 and set an “underweight” rating on the stock in a research note on Monday, April 21st. Jefferies Financial Group raised QuidelOrtho from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a report on Thursday, May 8th. Wall Street Zen upgraded QuidelOrtho from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Finally, UBS Group dropped their target price on QuidelOrtho from $45.00 to $29.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.33.

QuidelOrtho Stock Performance

Shares of QDEL stock opened at $28.70 on Friday. QuidelOrtho has a 12-month low of $23.77 and a 12-month high of $49.45. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.20 and a quick ratio of 0.66. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -5.77 and a beta of 0.10. The business has a 50 day simple moving average of $29.77 and a 200 day simple moving average of $36.04.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.13. The company had revenue of $692.80 million during the quarter, compared to analyst estimates of $694.97 million. QuidelOrtho had a positive return on equity of 4.71% and a negative net margin of 12.07%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.44 EPS. On average, equities research analysts anticipate that QuidelOrtho will post 2.3 EPS for the current year.

Hedge Funds Weigh In On QuidelOrtho

A number of institutional investors and hedge funds have recently bought and sold shares of QDEL. Focus Partners Wealth lifted its stake in shares of QuidelOrtho by 210.9% in the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock worth $715,000 after acquiring an additional 13,876 shares during the period. Royal Bank of Canada increased its stake in shares of QuidelOrtho by 1,218.7% during the first quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock valued at $2,803,000 after acquiring an additional 74,112 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in QuidelOrtho by 10.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after purchasing an additional 21,968 shares in the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.